Application 206316
- Type
- NDA
- Sponsor
- DAIICHI SANKYO INC
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | SAVAYSA | EDOXABAN TOSYLATE | TABLET;ORAL | EQ 15MG BASE | Yes | No |
| 002 | SAVAYSA | EDOXABAN TOSYLATE | TABLET;ORAL | EQ 30MG BASE | Yes | No |
| 003 | SAVAYSA | EDOXABAN TOSYLATE | TABLET;ORAL | EQ 60MG BASE | Yes | Yes |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 65597-201 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-201 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-201 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-201 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo | NDA | Current |
| 65597-201 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-201 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-202 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-202 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-202 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo | NDA | Current |
| 65597-202 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-202 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-202 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-203 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-203 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-203 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-203 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |
| 65597-203 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo | NDA | Current |
| 65597-203 | SAVAYSA | EDOXABAN TOSYLATE | Daiichi Sankyo Inc. | NDA | Current |